Overview

Assessment of LBR-101 In Chronic Migraine

Status:
Completed

Trial end date:
2015-03-31

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.

Phase:

Phase 2

Details

Lead Sponsor:

Teva Pharmaceutical Industries, Ltd.

Treatments:

Antibodies, Monoclonal